Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 4/20 | 0.37 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3499122 | 0.95 | AHR (0.42) | AHRAPPSMPD1PSEN1PSEN2 | |
| SCHEMBL7607190 | 0.89 | AHR (0.42) | AHRAPPSMPD1FDPS | |
| SCHEMBL6884013 | 0.88 | CHRNA7 (0.44) | AHR | |
| SCHEMBL235016 | 0.87 | LMNA (0.41) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31078471 | 0.83 | LMNA (0.44) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL26103495 | 0.83 | LMNA (0.44) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3628620 | 0.83 | LMNA (0.44) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL278733 | 0.83 | LMNA (0.44) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL18901651 | 0.83 | LMNA (0.44) | SMPD1PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6876942 | 0.83 | TRPA1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6824890-B2 | TOPOLOGICAL STRATEGY FOR DESIGNING AMORPHOUS MOLECULAR SOLIDS FOR FORMING THIN FILMS IN OPTOELECTRONIC DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2004-11-30 | — | — | US | disclosed |
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | NATIONAL SCIENCE FOUNDATION | 2003-03-20 | — | — | US | disclosed |
| WO-2001083410-A1 | SOLUBLE TETRAHEDRAL COMPOUNDS FOR USE IN ELECTROLUMINESCENT DEVICES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055278-A1 | Soluble tetrahedral compounds for use in electroluminescent devices | PAX3, EPCAM, PAXBP1 | AHR 2418/4885APP 2942/4885SMPD1 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.